Marker Therapeutics Inc (NASDAQ: MRKR) has reported a loss for its fourth fiscal quarter (ending December 31) of $-0.30 versus a loss $-0.04 for the same period a year ago. For the latest four quarters through December 31, E.P.S. were $-1.59 compared to $-0.24 a year ago.
Recent Price Action
Marker Therapeutics Inc (NASDAQ: MRKR) stock declined modestly by -1.4% on 3/25/24. The stock closed at $4.84. However, unusually low trading volume at 58% of normal accompanied the decline. The stock has been weak relative to the market over the last nine months but has risen 9.3% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be in line with the cost of capital, MRKR is expected to be Value Creation neutral.
Marker Therapeutics has a current Value Trend Rating of F (Lowest Rating). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. Marker Therapeutics has a poor Power Rating of 26 and a very low Appreciation Score of 9, triggering the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment